170 related articles for article (PubMed ID: 38224099)
1. Elinzanetant: a phase III therapy for postmenopausal patients with vasomotor symptoms.
Sassarini J; Anderson RA
Expert Opin Investig Drugs; 2024 Jan; 33(1):19-26. PubMed ID: 38224099
[TBL] [Abstract][Full Text] [Related]
2. Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
Pinkerton JV; Simon J; Panay N; Seitz C; Parke S; Caetano C; Mellinger U; Haseli Mashhadi N; Haberland C; Atanackovic G; Holz C; Mao G; Morrison M; Nisius S; Schaefers M; Zuurman L
Menopause; 2024 Jun; 31(6):522-529. PubMed ID: 38564691
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1).
Simon JA; Anderson RA; Ballantyne E; Bolognese J; Caetano C; Joffe H; Kerr M; Panay N; Seitz C; Seymore S; Trower M; Zuurman L; Pawsey S
Menopause; 2023 Mar; 30(3):239-246. PubMed ID: 36720081
[TBL] [Abstract][Full Text] [Related]
4. Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause.
Cieri-Hutcherson NE; Marji EK; Hutcherson TC
Menopause; 2024 Apr; 31(4):342-354. PubMed ID: 38471077
[TBL] [Abstract][Full Text] [Related]
5. Fezolinetant in the treatment of vasomotor symptoms associated with menopause.
Depypere H; Lademacher C; Siddiqui E; Fraser GL
Expert Opin Investig Drugs; 2021 Jul; 30(7):681-694. PubMed ID: 33724119
[No Abstract] [Full Text] [Related]
6. Menopause review: Emerging treatments for menopausal symptoms.
Patel B; S Dhillo W
Best Pract Res Clin Obstet Gynaecol; 2022 May; 81():134-144. PubMed ID: 34965909
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis.
Elnaga AAA; Alsaied MA; Elettreby AM; Ramadan A
Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():142-152. PubMed ID: 38640780
[TBL] [Abstract][Full Text] [Related]
8. Neurokinin 3 Receptor Antagonists Compared With Serotonin Norepinephrine Reuptake Inhibitors for Non-Hormonal Treatment of Menopausal Hot Flushes: A Systematic Qualitative Review.
Menown SJ; Tello JA
Adv Ther; 2021 Oct; 38(10):5025-5045. PubMed ID: 34514552
[TBL] [Abstract][Full Text] [Related]
9. New advances in menopause symptom management.
Koysombat K; McGown P; Nyunt S; Abbara A; Dhillo WS
Best Pract Res Clin Endocrinol Metab; 2024 Jan; 38(1):101774. PubMed ID: 37076317
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Low-Dose Paroxetine for the Treatment of Hot Flushes in Surgical and Physiological Postmenopausal Women: Systematic Review and Meta-Analysis of Randomized Trials.
Riemma G; Schiattarella A; La Verde M; Zarobbi G; Garzon S; Cucinella G; Calagna G; Labriola D; De Franciscis P
Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31480427
[No Abstract] [Full Text] [Related]
11. The neurokinin B pathway in the treatment of menopausal hot flushes.
Anderson RA; Skorupskaite K; Sassarini J
Climacteric; 2019 Feb; 22(1):51-54. PubMed ID: 30572747
[TBL] [Abstract][Full Text] [Related]
12. The role of kisspeptin/neurokinin B/dynorphin neurons in pathomechanism of vasomotor symptoms in postmenopausal women: from physiology to potential therapeutic applications.
Szeliga A; Czyzyk A; Podfigurna A; Genazzani AR; Genazzani AD; Meczekalski B
Gynecol Endocrinol; 2018 Nov; 34(11):913-919. PubMed ID: 29902942
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis.
Rahman UA; Kashif TB; Usman M; Rana M; Hasanain M; Anjum MU; Cheema HA; Jaffar H; Bhattarai P
Medicine (Baltimore); 2023 Dec; 102(50):e36592. PubMed ID: 38115258
[TBL] [Abstract][Full Text] [Related]
14. Assessment of women's treatment preferences for vasomotor symptoms due to menopause.
Shiozawa A; Thurston RC; Cook E; Yang H; King DD; Kristy RM; Mancuso S
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1117-1128. PubMed ID: 37650213
[TBL] [Abstract][Full Text] [Related]
15. Menopausal hot flushes and night sweats: where are we now?
Archer DF; Sturdee DW; Baber R; de Villiers TJ; Pines A; Freedman RR; Gompel A; Hickey M; Hunter MS; Lobo RA; Lumsden MA; MacLennan AH; Maki P; Palacios S; Shah D; Villaseca P; Warren M
Climacteric; 2011 Oct; 14(5):515-28. PubMed ID: 21848495
[TBL] [Abstract][Full Text] [Related]
16. Neurokinin 3 Receptor Antagonism: A Novel Treatment for Menopausal Hot Flushes.
Modi M; Dhillo WS
Neuroendocrinology; 2019; 109(3):242-248. PubMed ID: 30504731
[TBL] [Abstract][Full Text] [Related]
17. Resistance training reduced luteinising hormone levels in postmenopausal women in a substudy of a randomised controlled clinical trial: A clue to how resistance training reduced vasomotor symptoms.
Nilsson S; Henriksson M; Berin E; Engblom D; Holm AS; Hammar M
PLoS One; 2022; 17(5):e0267613. PubMed ID: 35617333
[TBL] [Abstract][Full Text] [Related]
18. Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women.
Pawsey S; Mills EG; Ballantyne E; Donaldson K; Kerr M; Trower M; Dhillo WS
J Clin Endocrinol Metab; 2021 Jul; 106(8):e3221-e3234. PubMed ID: 33624806
[TBL] [Abstract][Full Text] [Related]
19. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages.
Deecher DC; Dorries K
Arch Womens Ment Health; 2007; 10(6):247-57. PubMed ID: 18074100
[TBL] [Abstract][Full Text] [Related]
20. Neurokinin B and Neurokinin-3 Receptor Signaling: Promising Developments in the Management of Menopausal Hot Flushes.
Modi M; Dhillo WS
Semin Reprod Med; 2019 May; 37(3):125-130. PubMed ID: 31869840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
